Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Rises By 38.0%

Tharimmune, Inc. (NASDAQ:THAR) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 36,300 shares, an increase of 38.0% from the February 13th total of 26,300 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average trading volume of 98,300 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analyst Weigh In

THAR has been the topic of a number of research analyst reports. Rodman & Renshaw initiated coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price target on the stock. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.

Tharimmune Stock Performance

NASDAQ:THAR remained flat at $1.45 during trading hours on Friday. The company’s stock had a trading volume of 9,370 shares, compared to its average volume of 351,487. The company’s fifty day moving average is $1.85 and its 200 day moving average is $2.20. Tharimmune has a 12-month low of $1.28 and a 12-month high of $7.46.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC acquired a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).